AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More
Currently, some patients with chronic hepatitis B (CHB) can achieve clinical cure through interferon-based antiviral treatment. To pursue clinical cure for a larger population, there is a flurry of activity in the development of new drugs. Six studies on new therapies for hepatitis B were selected for presentation at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, to be discussed in the "Hepatitis B: New Therapies for HBV and HDV" session. Hepatology Digest has compiled this information for interested readers, and the session is scheduled for online access on November 12th at 8:30 AM local time.